Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.34 |
| ▸ | KIF18A | Q8NI77 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17523589 | 1.00 | IRAK4 (0.38) | IRAK4HRH3PTPN11HSD11B1OGA | |
| SCHEMBL17523597 | 0.94 | HSD11B1 (0.39) | IRAK4HRH3PTPN11HSD11B1OGA | |
| SCHEMBL17523596 | 0.94 | HSD11B1 (0.39) | IRAK4HRH3PTPN11HSD11B1OGA | |
| SCHEMBL30077146 | 0.93 | HSD11B1 (0.41) | IRAK4HRH3PTPN11HSD11B1OGA | |
| SCHEMBL15347418 | 0.93 | HSD11B1 (0.41) | IRAK4HRH3PTPN11HSD11B1OGA | |
| SCHEMBL23282469 | 0.93 | HSD11B1 (0.41) | IRAK4HRH3PTPN11HSD11B1OGA | |
| SCHEMBL15347211 | 0.93 | HSD11B1 (0.41) | IRAK4HRH3PTPN11HSD11B1OGA | |
| SCHEMBL30077052 | 0.93 | HSD11B1 (0.41) | IRAK4HRH3PTPN11HSD11B1OGA | |
| Usl-311 SCHEMBL17523587 | 0.92 | HRH3 (0.39) | IRAK4HRH3PTPN11HSD11B1OGA | |
| SCHEMBL17523591 | 0.88 | ACKR3 (0.38) | IRAK4HRH3PTPN11HSD11B1OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-9353086-B2 | CXCR4 receptor antagonists | PROXIMAGEN LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226106-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | IRAK4 1107/4885HRH3 288/4885PTPN11 928/4885 |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | IRAK4 1107/4885HRH3 288/4885PTPN11 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.